Benign Conditions

The method involves local delivery of the antibiotic gentamicin directly into the bladder tissue.

Check out the key regulatory decisions set to happen early this year.

In a recent study of the RELIEF stent, 95% of patients showed no VUR following stent placement.

"The goal for this study was to understand, over the lifetime in individuals with spina bifida, what bacteria are present in their urine normally, what bacteria are present when they have a UTI, and what are some important clinical differences we can tease out to help understand which patients should really be treated," says Brendan T. Frainey, MD.

Catch up on all the notable drug and device approvals in urology over the past year.

A rapid reduction in E coli in the urine was observed among 10 of 16 evaluable patients at 4 hours following the first treatment.

The approval is supported by data from the phase 3 SURE 1 and REASSURE trials.

According to iota Biosciences, the device is “designed to deliver electrical stimulation directly to the bladder wall, inducing contractions that facilitate bladder emptying in individuals impacted by underactive bladder.”

“What probably should be happening is that we should be reserving these antibiotics only for those situations in which someone has a multi-drug-resistant infection for which there are options that are not available otherwise,” says A. Lenore Ackerman, MD, PhD.

"A global consensus on standardization of terminology, separation of LUTS vs pain for outcome, HL positivity and negativity, markers for disease, and the role of new interventions for local vs systemic therapy is needed," writes Gopal H. Badlani, MD.

"It's really upon us, as the medical community, to be better about not just antibiotic stewardship, but also diagnostic stewardship," says A. Lenore Ackerman, MD, PhD.

Follow Urology Times' coverage of the full-day FDA advisory committee meeting regarding Iterum Therapeutics' new drug application for oral sulopenem for uncomplicated urinary tract infection.

“We are finding more and more information and evidence to support recommendations to try and reduce the infection rates,” says Christian Moro, PhD, BSc, BEd, MBus, SFHEA.

"A lot of studies were done in a way that weren't randomized," says Christian Moro, PhD, BSc, BEd, MBus, SFHEA.

"We're actually standardizing how to clean the catheter, because the system tells you exactly [how]," says Ana Lidia Flores-Mireles, PhD.

"We ended up with 3091 participants overall, and 3 trends came out that were significant," says Christian Moro, PhD, BSc, BEd, MBus, SFHEA.

"One of the things that's been identified is over 90% of the UTI presentations have found bugs that are antibiotic resistant," says Christian Moro, PhD, BSc, BEd, MBus, SFHEA.

"We had a really clear idea...[We were looking at] how we can better optimize the system for cleaning," says Ana Lidia Flores-Mireles, PhD.

"Teixobactin, and more broadly, the iChip approach to novel antibiotic discovery, is an exciting development in infection control," write Philip Abbosh, MD, PhD, and Kate Gessner, MD, PhD.

“Our goal is to support patients throughout their entire journey with an intelligence chat system that not only evaluates them, but also answers many questions when their treating physician is not available, which is very common,” says Juan Fulla, MD, MSc.

“I think in terms of symptom elicitation, it's important to be systematic so that we don't shortchange certain populations when we try to figure out what their symptoms are,” says Briony K. Varda, MD, MPH.

"The objective of this study was to assess baseline knowledge about urinary tract infections, interest in health resources, and platform preferences for health information acquisition and dissemination," says Stephanie Gleicher, MD.

"I can say that I do see a vast number of different types of patient populations," says Adity Dutta, MSN, AGACNP-BC.

"I think these findings are critical in helping us craft educational resources that would be easily understood and easily disseminated by trusted health care providers," says Stephanie Gleicher, MD, MPH.

"This study reinforces our role as physicians to guide patients away from costly supplements with little or no benefit," said Wai Lee, MD.

"I think having success with that in humans will make [radiofrequency ablation] very, very valuable for the practicing urologist that can be done in the clinic without much training or anything like that," says Gamal M. Ghoniem, MD, FACS, ABU/FPMRS.

"Glean technology is a very brilliant technology that has been developed for basically portable urodynamics," says Zhina Sadeghi, MD.

"We...found that about 50% of women felt like infections are caused by lack of cleanliness and tight-fitting clothes," says Stephanie Gleicher, MD.

"What we believe is happening is women are seeking the help of female urologists, and therefore, because of the nature of the condition, the female urologists are absorbing the burden of the care of these patients, particularly the non-billable burden," says Debra L. Fromer, MD.

"With regards to barriers to attaining health information, we found that a lot of women reported that medical language is just too complex," says Stephanie Gleicher, MD, MPH.